4-(4乙基哌嗪-1-基)苯甲醛 | 197638-76-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(4乙基哌嗪-1-基)苯甲醛
• 中文别名: 4-(4-乙基哌嗪-1-yl)苯甲醛；4-(4-乙基哌嗪-1-基)苯甲醛
• 英文名称: 4-(4-ethylpiperazin-1-yl)benzaldehyde
• CAS: 197638-76-9
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: UXVDOPUAJVRFDG-UHFFFAOYSA-N

物化性质

• 沸点：
  364.6±37.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Ethylpiperazin-1-yl)benzaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Ethylpiperazin-1-yl)benzaldehyde
CAS number: 197638-76-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H18N2O
Molecular weight: 218.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4乙基哌嗪-1-基)苯甲醛 在 sodium tetrahydroborate 、 乙醇 作用下， 反应 18.0h， 以0.3 g的产率得到4-(4-乙基哌嗪-1-基)苯甲醇
  参考文献：
  名称：

  [EN] USE OF DISUBSTITUTED BENZENES TO CONTROL INSECTICIDE-RESISTANT PESTS
  [FR] UTILISATION DE BENZÈNES DISUBSTITUÉS POUR LUTTER CONTRE DES ORGANISMES NUISIBLES RÉSISTANTS AUX INSECTICIDES

  摘要：

  这项发明属于昆虫控制技术领域，涉及使用二取代苯类化合物来控制对杀虫剂具有抗性的害虫，如蚊子和蟑螂。

  公开号：

  WO2018202681A1
• 作为产物：
  描述：

  4-哌嗪基苯甲腈 在 三乙酰氧基硼氢化钠 、 二异丁基氢化铝 、 溶剂黄146 作用下， 以 正己烷 、 二氯甲烷 、 甲苯 为溶剂， 反应 12.5h， 生成 4-(4乙基哌嗪-1-基)苯甲醛
  参考文献：
  名称：

  合成具有5,11-二氢-6H-吡啶并[2,3-b] [1,4]苯并二氮杂-6-骨架作为有效和选择性的M2毒蕈碱受体拮抗剂的新型琥珀酰胺衍生物。二。

  摘要：

  制备了一系列含有5,11-二氢-6H-吡啶并[2,3-b] [1,4]苯并二氮杂-6-6骨架（6a-z）的琥珀酰胺衍生物，并评估了其与毒蕈碱受体的结合亲和力。与AF-DX 116（1a）相比在体外以及对心动过缓和体内唾液的拮抗作用。体外结构-活性关系（SAR）研究表明，4-（4-烷基-1-哌嗪基）苄氨基部分在增强与M2毒蕈碱受体的亲和力中起关键作用。含有4-（4-异丙基-1-哌嗪基）苄基甲基氨基的化合物6y对M2毒蕈碱受体的亲和力最高（pKi = 9.2），效力是1a的200倍，而化合物6u含有4-（与M3毒蕈碱受体相比，4-乙基-1-哌嗪基）苄基乙基氨基部分显示出最高的M2选择性（M3 / M2比= 320）。静脉或口服给药后，6y和6u均能拮抗氧代雷斯莫林诱导的大鼠心动过缓。有意识的狗的口服评估表明，提高心率的功效至少是1a的3倍。

  DOI：

  10.1248/cpb.45.1458

文献信息

• ANTI-HIV COMPOUNDS
  申请人：Prosetta Antiviral, Inc.

  公开号：US20160168100A1

  公开（公告）日：2016-06-16

  This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.

  这项发明提供了用于治疗病毒感染的四氢异喹啉等化合物，含有这类化合物的药物配方，以及抑制病毒（如HIV）复制或治疗疾病（如艾滋病）的方法。
• [EN] CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS<br/>[FR] COMPOSÉS AZAARYL SUBSTITUÉS PAR LE CHLOROBENZÈNE
  申请人：UNIV TAIPEI MEDICAL

  公开号：WO2017015400A1

  公开（公告）日：2017-01-26

  The invention provides a series of chlorobenzene substituted azaaryl compounds having activity in inhibiting cancer cell growth and low toxicity to normal cells. Particularly, the compounds of the invention have stronger inhibition effect on bladder cancer and liver cancer.

  该发明提供了一系列氯苯取代的氮杂芳基化合物，具有抑制癌细胞生长并对正常细胞毒性较低的活性。特别是，该发明的化合物对膀胱癌和肝癌具有更强的抑制作用。
• Synthesis of Novel Benzazole Derivatives and Evaluation of Their Antidepressant-Like Activities with Possible Underlying Mechanisms
  作者：Gamze Tokgöz、Ümide Demir Özkay、Derya Osmaniye、Nazlı Turan Yücel、Özgür Can、Zafer Kaplancıklı

  DOI：10.3390/molecules23112881

  日期：——

  These data indicated that compounds 4a, 4b, 4e and 4f possess significant antidepressant-like activities. Moreover, pre-treatments with p-chloro-phenylalanine methyl ester (an inhibitor of serotonin synthesis), NAN-190 (a 5-HT1A antagonist), ketanserin (a 5-HT2A/2C antagonist), and ondansetron (a 5-HT3 antagonist) reversed the exhibited pharmacological effects. Results of the mechanistic studies suggested

  通过相应的 2-（苯并唑-2-基硫基）乙酰肼与适当的 4-取代苯甲醛反应，得到新型苯并唑衍生物化合物 4a-4h。通过FT-IR、1H-NMR、13C-NMR和LCMS光谱方法阐明了合成化合物的化学结构。通过悬尾试验（TST）和改良的强迫游泳试验（MFST）评估化合物的抗抑郁样作用。此外，通过活动笼装置评估动物的运动活动。在该系列中，化合物 4a、4b、4e 和 4f（50 mg/kg）显着降低了小鼠在 TST 和 MFST 中的不动时间。相同的化合物延长了动物在 MFST 中的游泳时间，而攀爬持续时间没有任何变化。这些数据表明化合物 4a、4b、4e和4f具有显着的抗抑郁样活性。此外，使用对氯苯丙氨酸甲酯（一种血清素合成抑制剂）、NAN-190（一种 5-HT1A 拮抗剂）、酮色林（一种 5-HT2A / 2C 拮抗剂）和昂丹司琼（一种 5-HT3拮抗剂）逆转了所表现出的药理作用。机理研
• Optimization of Imidazo[4,5-<i>b</i>]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia
  作者：Vassilios Bavetsias、Simon Crumpler、Chongbo Sun、Sian Avery、Butrus Atrash、Amir Faisal、Andrew S. Moore、Magda Kosmopoulou、Nathan Brown、Peter W. Sheldrake、Katherine Bush、Alan Henley、Gary Box、Melanie Valenti、Alexis de Haven Brandon、Florence I. Raynaud、Paul Workman、Suzanne A. Eccles、Richard Bayliss、Spiros Linardopoulos、Julian Blagg

  DOI：10.1021/jm300952s

  日期：2012.10.25

  children with acute myeloid leukemia (AML), conferring a poor prognosis in both age groups. In an in vivo setting, 27e strongly inhibited the growth of a FLT3-ITD-positive AML human tumor xenograft (MV4–11) following oral administration, with in vivo biomarker modulation and plasma free drug exposures consistent with dual FLT3 and Aurora kinase inhibition. Compound 27e, an orally bioavailable dual FLT3 and

  对基于咪唑并[4,5 - b ]吡啶的系列极光激酶抑制剂进行优化，鉴定出 6-chloro-7-(4-(4-chlorobenzyl)pirazin-1-yl)-2-(1, 3-dimethyl-1 H -pyrazol-4-yl)-3 H -imidazo[4,5- b ]pyridine ( 27e )，一种强效的 Aurora 激酶抑制剂 (Aurora-A K d = 7.5 nM, Aurora-B K d = 48 nM)、FLT3 激酶 ( K d = 6.2 nM) 和 FLT3 突变体，包括 FLT3-ITD ( K d = 38 nM) 和 FLT3(D835Y) ( K d = 14 nM)。FLT3-ITD 引起组成型 FLT3 激酶激活，在 20-35% 的成人和 15% 的急性髓性白血病 (AML) 患儿中检测到，这两个年龄组的预后都很差。在体内环境中，27e在口服给药后强烈抑制FLT3
• Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson’s disease
  作者：Wei Li、Xia Yang、Qing Song、Zhongcheng Cao、Yichun Shi、Yong Deng、Li Zhang

  DOI：10.1016/j.bioorg.2020.103707

  日期：2020.4

  A series of pyridoxine-resveratrol hybrids were designed and synthesized as monoamine oxidase B inhibitors for the treatment of Parkinson’s disease. Most of them exhibited potent inhibitory activities on MAO-B with high selectivity. Specifically, compounds 12a, 12g and 12l showed the most excellent inhibition to hMAO-B with the IC50 values of 0.01 μM, 0.01 μM and 0.02 μM, respectively. Further reversibility

  设计并合成了一系列吡ido醇-白藜芦醇杂化物作为单胺氧化酶B抑制剂，用于治疗帕金森氏病。它们大多数以高选择性对MAO-B表现出有效的抑制活性。具体地，化合物12a，12g和12l对h MAO-B表现出最优异的抑制，IC 50值分别为0.01μM，0.01μM和0.02μM。进一步的可逆性研究表明12a和12l是可逆的，而12g是可逆的是不可逆的MAO-B抑制剂。MAO的分子对接研究揭示了这些化合物与MAO-B的结合模式和高选择性。另外，在对H 2 O 2诱导的PC-12细胞损伤的测试中，这三种代表性化合物还表现出低细胞毒性和优异的神经保护作用。而且，12a，12g和12l显示出良好的抗氧化活性和高的血脑屏障渗透性。总体而言，所有这些结果突出了12a，12g和12l是用于PD治疗的潜在且优异的MAO-B抑制剂。